MedTrace Logo

Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

NCT03437967 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-08-26

No results posted yet for this study

Summary

This study will examine the effect of LASER photobiomodulation therapy on pain and opioid pain medication weaning on patients who are undergoing opioid pain medication weaning.

Conditions

Interventions

DEVICE

LightForce EXPi

LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.

Sponsors & Collaborators

  • LiteCure LLC

    lead INDUSTRY

Principal Investigators

  • Jerome C Stenehjem, Md · Sharp HealthCare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-06-01
Completion
2019-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437967 on ClinicalTrials.gov